key: cord-1025145-kol3337f
authors: Lima, William G.; Brito, Júlio C. M.; da Cruz Nizer, Waleska S.
title: Bee products as a source of promising therapeutic and chemoprophylaxis strategies against COVID‐19 (SARS‐CoV‐2)
date: 2020-09-18
journal: Phytother Res
DOI: 10.1002/ptr.6872
sha: f52d2808a2dc5565dfdf15e999cf7fc0fbf673c8
doc_id: 1025145
cord_uid: kol3337f

The emergence of novel coronavirus (SARS‐CoV‐2) in 2019 in China marked the third outbreak of a highly pathogenic coronavirus infecting humans. The novel coronavirus disease (COVID‐19) spread worldwide, becoming an emergency of major international concern. However, even after a decade of coronavirus research, there are still no licensed vaccines or therapeutic agents to treat the coronavirus infection. In this context, apitherapy presents as a promising source of pharmacological and nutraceutical agents for the treatment and/or prophylaxis of COVID‐19. For instance, several honeybee products, such as honey, pollen, propolis, royal jelly, beeswax, and bee venom, have shown potent antiviral activity against pathogens that cause severe respiratory syndromes, including those caused by human coronaviruses. In addition, the benefits of these natural products to the immune system are remarkable, and many of them are involved in the induction of antibody production, maturation of immune cells, and stimulation of the innate and adaptive immune responses. Thus, in the absence of specific antivirals against SARS‐CoV‐2, apitherapy could offer one hope toward mitigating some of the risks associated with COVID‐19.

The emergence of novel coronavirus (SARS-CoV-2) in 2019 in China marked the third outbreak of a highly pathogenic coronavirus infecting humans. The novel coronavirus disease (COVID-19) spread worldwide, becoming an emergency of major international concern. However, even after a decade of coronavirus research, there are still no licensed vaccines or therapeutic agents to treat the coronavirus infection. In this context, apitherapy presents as a promising source of pharmacological and nutraceutical agents for the treatment and/or prophylaxis of COVID-19. For instance, several honeybee products, such as honey, pollen, propolis, royal jelly, beeswax, and bee venom, have shown potent antiviral activity against pathogens that cause severe respiratory syndromes, including those caused by human coronaviruses. In addition, the benefits of these natural products to the immune system are remarkable, and many of them are involved in the induction of antibody production, maturation of immune cells, and stimulation of the innate and adaptive immune responses. Thus, in the absence of specific antivirals against SARS-CoV-2, apitherapy could offer one hope toward mitigating some of the risks associated with COVID-19. (Lim et al., 2016; Park, 2020) . This most recent outbreak started as a set of pneumonia cases in the city of Wuhan (Hubei province, China), which were associated with a betacoronavirus named the novel coronavirus of 2019 (2019-nCov) (Zhu et al., 2020a) . Thereafter, the 2019-nCov genome sequence revealed 89% similarity and 80% identity with SARS-CoV, and the International Virus Taxonomy Committee renamed the 2019-nCov as SARS-CoV-2 (Lee et al., 2014) .

COVID-19 is an infectious disease caused by SARS-CoV-2 that affects the lower respiratory tract and hematological system, in which its main clinical signs, such as fever, cough, and shortness of breath, are similar to other viral pneumonia (Deng et al., 2020; Zhai et al., 2020) . The transmission of COVID-19 occurs mainly from person to person through droplets produced by coughing or sneezing or through direct contact with an infected individual (Zhai et al., 2020) . Several preventive measures, such as social distancing and lockdown of cities, have been adopted to control the COVID-19 pandemic. However, these stringent measures have not been sufficient to control the high transmissibility of SARS-CoV-2 in some regions, which has become a public health threat worldwide (Park, 2020) . SARS-CoV-2 has already infected more than 20 million people and caused approximately 800,000 deaths in virtually all countries around the world (Coronavirus Cases, 2020) .

Due to the public health crisis created by researchers have focused on the identification of drugs with therapeutic or prophylactic potential for the treatment and control of this viral infection.

In this context, several studies have highlighted the advantages of the drug repurposing strategy, which aims to identify new uses for FDAapproved drugs. For instance, some research centers have reported the promising therapeutic effects of hydroxychloroquine/chloroquine, remdesivir, lopinavir/ritonavir, ivermectin, and dexamethasone against severe cases of COVID-19 (Ahn et al., 2020; Zhai et al., 2020) . In addition, recent advances in immunotherapy have focused on mRNA SARS-CoV-2, and adenovirus type-5 vectored vaccines with promising preliminary data of safety, tolerability, and immunogenicity against COVID-19 (Ahn et al., 2020; Zhu et al., 2020b) . However, to date, no specific antiviral agent or licensed vaccine is available to treat or prevent COVID-19, and the control of the disease is still restricted to social distancing and isolation (Zhai et al., 2020) .

Apitherapy is a promising source of pharmacological and nutraceutical agents for the treatment and prophylaxis of COVID-19. Several honeybee products, such as honey, pollen, propolis, royal jelly, beeswax, and bee venom, have shown potent antiviral activity against pathogens that cause severe respiratory syndromes, including those caused by CoVh (Brown, Roberts, Cooper, & Jenkins, 2016; Hashem, 2020) . In addition, the benefits of these natural products to the immune system are remarkable, and many of them are involved in the induction of antibody production, maturation of immune cells, and stimulation of the innate and adaptive immune responses (Babaei, Rahimi, Karimi, Tahmasebi, & Khaleghi Miran, 2016) (Figure 1 ). Therefore, in this mini-review, we aim to present the therapeutic effects associated with several bee products that might be useful in the fight against the pandemic of the novel coronavirus (SARS-CoV-2).

Honey is a versatile and complex natural product formed from nectar, aphids excretion, or plant and fruit exudates. This honeybee product is composed of several bioactive chemicals that vary with the type of bee and environmental conditions (Meo, Al-Asiri, Mahesar, & Ansari, 2017; Samarghandian, Farkhondeh, & Samini, 2017) . The use of honey to treat microbial infections by ancient civilizations, such as Greeks, Chinese, Egyptians, Romans, Mayans, and Babylonians, dates back more than 5500 years (Meo et al., 2017) . For instance, honey was used in traditional medicine to treat several viral respiratory diseases, such as bronchitis, throat infections, pneumonia, and flu (Samarghandian et al., 2017) . Watanabe, Rahmasari, Matsunaga, Haruyama, and Kobayashi (2014) showed that the Manuka honey from Australia and New Zealand inhibited the viral replication of the influenza virus in vitro (IC 50 3.6 ± 1.2 mg/mL) due to its virucidal effects and its synergistic interaction with the antivirals zanamivir or oseltamivir. Thus, this study corroborates to better understand the antiviral effect of honey against respiratory viruses (Watanabe et al., 2014) .

The antiviral activity of some types of honey has been attributed to several properties, including its osmotic effect, naturally low pH, and the presence of several natural compounds (e.g., hydrogen peroxide, phenolic acids, flavonoids, and lysozyme) (Samarghandian et al., 2017) . Flavonoids, such as quercetin and its derivatives (e.g., rutin, isorhamnetin, quercitrin, and isoquercetin), are often found in propolis and honey samples, and have presented antiviral activity against influenza virus (Choi, Song, & Kwon, 2011; Dayem, Choi, Kim, & Cho, 2015) , human respiratory syncytial (Kaul, Middleton, & Ogra, 1985) , human rhinovirus (Ganesan et al., 2012; Song, Park, Kwon, & Choi, 2013) , human metapneumovirus (Komaravelli et al., 2015) , parainfluenza (Kaul et al., 1985) , and betacoronavirus (SARS-CoV) (Yi et al., 2004) . It is suggested that these compounds inhibit the 3-chymotrypsin-like cysteine protease (3C-like pro ) of hCoV (SARS-CoV). This enzyme is one of the most promising targets for drug discovery against coronaviruses due to its critical role in the viral life cycle (Chen et al., 2006) . However, the antiviral effect of honey against the novel coronavirus (SARS-CoV-2) has not been confirmed yet. A recent analysis of computational chemistry suggested the potential action of honey against SARS-CoV-2. Hashem (2020), through the molecular modeling approach, showed that six honeybee and propolis compounds (3-phenyllactic acid, caffeic acid phenethyl ester [CAPE] , lumichrome, galangin, chrysin, and caffeic acid) are potential inhibitors of SARS-CoV-2 3C-like pro (Hashem, 2020) .

Besides its promising antimicrobial activity, honey also stimulates the immune system and improves immunocompetence, which might reduce the severity of the novel coronavirus pneumonia. For instance, F I G U R E 1 Schematic representation of the main effects of bee products that can be exploited against the novel coronavirus (SARS-CoV-2) [Colour figure can be viewed at wileyonlinelibrary.com] the addition of honey to drinking water (22 g/L ad libitum) increased the production of antibodies against the avian influenza virus H9N2, and reduced the heterophil/lymphocyte ratio in Japanese quails, confirming that honey improves the immune response against this virus (Babaei et al., 2016) .

Due to its promising antiviral activity, clinical trials have been conducted to confirm the effect of honey against SARS-CoV-2. A phase 3 randomized, multicenter, and controlled study is analyzing the therapeutic benefits of honey supplementation (1 g/kg/day divided into 2-3 doses for consecutive 14 days) in patients with COVID-19 (National Clinical Trial Number: NCT04323345) (Table 1 ). In another clinical trial, a group from Pakistan aims to evaluate the effectiveness of Nigella sativa/Black Cummins (1 mg orally) and honey (30 mL at 12/12 hours) in clearing the SARS-CoV-2, lowering the severity of COVID-19 symptoms and decreasing the mortality rate (National Clinical Trial Number: NCT04347382). The results of these clinical trials, as well as other preclinical studies, will indicate the benefit of honey in the pharmacotherapy of COVID-19 (Table 1) .

However, several clinical and preclinical studies (Table 2) (Cianciosi et al., 2018) . Thus, the botanical and geographical origin of honey is essential factors to guarantee comparability between different studies and should be determined whenever possible.

Propolis (bee glue) is a resinous substance produced by honeybees from substances collected from different parts of plants, such as leaves, flowers, buds, and exudates. Due to its properties, honeybees use propolis in the construction and adaptation of their hives (Anjum et al., 2019) . In general, propolis is composed of approximately 50% resins, 30% waxes, 10% essential oils, 5% pollen, and 5% various organic compounds, including polyphenols, flavonoids, amino acids, minerals, ethanol, vitamin A, vitamin B complex, and vitamin E (Anjum et al., 2019; Siheri, Alenezi, Tusiimire, & Watson, 2017) . Because propolis is commonly used as an antimicrobial agent against bacteria, viruses, and other pathogenic micro-organisms that attack the hives (Anjum et al., 2019) , several studies have aimed to investigate its activity against relevant human pathogens (Siheri et al., 2017) . In this context, propolis showed promising antiviral effects in vitro and in vivo against influenza virus (Shimizu et al., 2008) , human respiratory syncytial (Tomomi Takeshita et al., 2013) , and human rhinovirus (Kwon, Shin, Perumalsamy, Wang, & Ahn, 2019) .

The antiviral activity of propolis is associated with the presence of phenolic compounds (e.g., galangin, chrysin, p-coumaric acid, kaempferol, and quercetin), which block or reduce the adsorption and entrance of the virus into the host cells (Kwon et al., 2019; Schnitzler et al., 2010) . Since these are considered early steps of the viral cycle, the use of propolis may be more suitable for chemoprophylaxis. Furthermore, similar to honey, propolis is known to stimulate the adaptive immune response, which reinforces its prophylactic antiviral effect (Babaei et al., 2016) . 

Royal jelly is a hypo-pharyngeal glandular white-yellowish excretion, gelatinous-viscous sour taste and, a slight smell of phenol. It is produced by young worker honeybees and is used in the nutrition of larvae and adult queens. Royal jelly is an acid colloid (3.6-4.2 pH) composed of water (60%-70%), sugar (12%-15%), proteins (12%), lipids (5%-6%), and low amounts of vitamins and mineral salts (Fratini, Cilia, Mancini, & Felicioli, 2016a) .

Some studies have shown that raw or purified royal jelly has notable antimicrobial activity. The use of royal jelly alone or in combination with propolis reduced the in vitro viral load of cells infected with the influenza virus A2 (Filipic & Likar, 1976a ). In addition, clinical evidence shows that the combination of royal jelly with other bee products prevents infection during influenza outbreaks. For instance, the frequency of flu was significantly lower (3.7% incidence) among patients who used an apicomplex composed of honey, royal jelly (2%), pollen (3%), and propolis (1%) in comparison with untreated patients (38% incidence) (Filipic & Likar, 1976aa) . However, the authors do not make (Table 2) .

Besides the antiviral effect exhibited by royal jelly, it can also be used as a prophylactic agent due to its benefits to the immune tone. A study with mice revealed a higher production of antibodies and immunocompetent cell proliferation among animals that received the royal jelly supplementation (0.1 mL of royal jelly s.c. by 7 days) (Šver et al., 1996) . These results highlight the therapeutic and prophylactic potential of royal jelly and its components against human respiratory syndromes, such as the causative agent of the current pandemic, that is,

Importantly, some peptides isolated from royal jellies, such as 2.5 μg/mL; Jelleine-II: 2.5 μg/mL) in vitro (Fontana et al., 2004) . As shown by Lansbury et al. (2020) , those are species frequently recovered from patients hospitalized with COVID-19, thus suggesting the benefits of royal jelly in preventing co-infections.

Beeswax is a complex lipid-based organic compound secreted in a liq- 

Clinical evidence of activity against SARS-CoV-2

The clinical trial has been currently conducted against SARS-CoV-2

Pre-clinical (in vitro or in vivo) evidence of antiviral activity (except against SARS-CoV-2)

Clinical evidence of antiviral activity (except against SARS-CoV-2)-prophylaxis

Clinical evidence of antiviral activity (except against SARS-CoV-2)-Treatment " " of more than 300 compounds, including fatty acid esters (67%), hydrocarbons (12%-16%), free fatty acids (12%-14%), fatty alcohol (1%), diesters, and exogenous substances, such as residues of propolis, pollen, and small pieces of floral component factors (Fratini, Cilia, Mancini, & Felicioli, 2016a) .

In recent years, the effect of the crude extract of beeswax and its methanol, acetone, and ethanol extracts against pathogenic bacteria and fungi have been studied (Fratini, Cilia, Turchi, & Felicioli, 2016b) .

Regarding its antiviral activity, only one study has been identified. Mohamed, Hassan, Hammad, Amer, and Riad (2015) showed the antiviral effect of four beeswax extracts (i.e., ethanol white beeswax (EWBW), ethanol black beeswax (EBBW), acetone white beeswax (AWBW), and acetone black beeswax (ABBW)) against DNA (adenovirus-7) and RNA (Rift Valley fever virus) viruses (Mohamed et al., 2015) . In this study, the treatment of Vero cells infected by human adenovirus serotype 7 (adenovirus-7) with ABBW and EBBW (100 μg/mL) reduced the viral load in 55.33% and 16.50% compared to untreated cells, respectively. On the other hand, the effect of beeswax against Rift Valley fever virus (RVFV) was less pronounced. All extracts decreased the viral title by less than 10% (ABBW and EWBW: 5.16% and AWBW and EBBW: 7.69%) when compared to infected cells (Mohamed et al., 2015) . These results show that beeswax acts mainly against DNA viruses, and its antiviral effect is dependent on the conditions of extraction employed and botanical origin of beewaxs. SARS-CoV-2, similar to RVFV, is an enveloped and singlestranded RNA virus that can be sensitive to the antiviral effects of beeswax extracts. However, no preclinical evidence has been found to support this hypothesis since the antiviral effect of beeswax has been poorly explored (Table 2) . We encourage more studies to assess the potential of beeswax supplementation as a strategy to fight viral infections, especially those caused by respiratory viruses such as influenza virus and SARS-CoV-2.

Pollen is a fine powder produced by flowering plants and collected by bees. When mixed with nectar (and/or honey) and salivary substances, it is used as the main food reserve for the hive (Denisow & Denisow-Pietrzyk, 2016; Thakur & Nanda, 2020) . Bee pollen is composed of proteins (5%-60%), essential amino acids, reducing sugars (13%-55%), lipids (4%-7%), nucleic acids (especially RNA), crude fiber (0.3%-20%), and minor components, such as minerals (Ca, Mg, Fe, Zn, Cu, K, and Na), vitamins (provitamin A [β-carotene], vitamin E [tocopherol], niacin, thiamine, biotin, and folic acid), enzymes, phytosterols (β-sitosterol, P-sitosterol, and terpenes), flavonoids (catechins, kaempferol, quercetin, and isorhamnetin), and organic carotenoid pigments (lycopene and zeaxanthin) (Thakur & Nanda, 2020) .

Bee pollen has been used in chemoprophylaxis of several infectious diseases as it has been shown to enhance the immunity of birds (Babaei et al., 2016) , mice (Küpeli Akkol, Orhan, Gürubüz, & Yesilada, 2010), and humans (Filipic & Likar, 1976b) . Although some studies have reported the antibacterial activity of extracts obtained from bee pollen against Gram-positive and Gram-negative bacteria, none of them has revealed its antiviral properties (Fatrcová-Šramková et al., 2013; M arg aoan et al., 2015) .

However, many of the compounds present in bee pollen, especially polyphenols, have promising activity against CoVhs, such as SARS-CoV and MERS (Chen et al., 2006; Yi et al., 2004) . Eight different types of phenolic compounds have been identified in bee pollen by high-performance liquid chromatography analysis. These compounds can be divided into two groups: flavonoids, represented by flavonols, flavones, flavanols, flavanones, anthocyanidin, chalcones, and isoflavones; and non-flavonoids compounds, such as phenolic acids (Denisow & Denisow-Pietrzyk, 2016; Thakur & Nanda, 2020) .

The phenolic phytochemicals with higher concentrations in bee pollen are quercetin and kaempherol, as well as their glycosides derivates (Rzepecka-Stojko et al., 2015) . According to Yi et al. (2004) , quercetin inhibited the entry of SARS-CoV into Vero E6 cells in vitro. The concentration required to inhibit 50% of SARS-CoV (EC 50 ) was 83.4 μM, which is a relatively low value considering the high concentration of this compound in the bee pollen (60 μmol/g of quercetin in pollen of Apis mellifera L.) (Carpes et al., 2013) . Additionally, quercetin-3β-galactoside, a glycoside derived from quercetin frequently found in bee pollen (Rzepecka-Stojko et al., 2015) , binds to SARS-CoV 3CL pro and inhibits its proteolytic activity with an IC 50 of 42.79 ± 4.95 μM. This inhibitory effect of SARS-CoV 3CL pro depends on the hydroxyl group of quercetin, which forms a hydrogen bond with the Gln189 residue present on the active site of 3CL pro (Chen et al., 2006) . Because SARS-CoV-2 3CL pro maintains the same residue Gln189 in its active site, it is suggested that the main protease of the novel coronavirus may also be sensitive to the inhibitory action of quercetin and its derivatives. Importantly, a recent computational study revealed that quercetin is predicted to form a hydrogen bond with Gln186 on active site of SARS-CoV-2 3CL pro , which results in low binding energy (−7.5 kcal/mol) and consequent high binding affinity (3.2 × 10 5 M −1 ) (Rehman, AlAjmi, & Hussain, 2020) .

Kaempferol and its glycoside analogs inhibit the 3a channel protein of coronavirus. The 3a protein forms a cation-selective channel that becomes expressed in the infected cell and is involved in the mechanism of virus release. Drugs that inhibit the ion channel can, therefore, inhibit virus release, becoming a source for the development of novel therapeutic antiviral agents against SARS-CoV-2 (Brockway & Denison, 2004; Li et al., 2020) . Schwarz et al. (2014) showed that in oocytes from

Xenopus laevis (African clawed frog) with expressed SARS-CoV 3a protein, Ba 2+ -sensitive current is weakly inhibited by Kaempeferol at 40 μM. In contrast to aglicone, the tested kaempferol glycosides hardly affected Ba 2+ -sensitive endogenous current. Juglanin is the most potent kaempferol glycoside against SARS-CoV 3a protein (IC 50 2.3 μM), followed by tiliroside, afzelin, and kaempferol-3-O-α-rhamnopyranosyl

(1 ! 2)[α-rhamnopyranosyl(1 ! 6)]-β-glucopyranoside (Schwarz et al., 2014) . Moreover, a molecular docking study revealed that Kaempferol might also act on SARS-CoV-2 3CL pro , showing binding energy and binding affinity of −7.8 kcal/mol and 5.2 × 10 5 M −1 , respectively. It forms two hydrogen bonds, in which the one with the Gln189 residue described previously is critical to the catalytic activity of 3CL pro (Rehman et al., 2020) .

Furthermore, quercetin and kaempferol exhibit inhibitory effects on inflammatory (IL-6, IL-8, IFN-γ, iNOS, COX-2, NF-κB, and TNF-α) (Pan, Lai, & Ho, 2010) and oxidative stress (LOX-1, RNS, and ROS) (Banjarnahor & Artanti, 2014) mediators. It suggests that they could also prevent immunologic complications associated with COVID-19, such as the macrophage activation syndrome (also known as secondary hemophagocytic lymphohistiocytosis), which results in a potentially fatal "cytokine storm" and acute respiratory distress syndrome (Biancatelli, Berrill, Catravas, & Marik, 2020) . Thus, the anti-inflammatory and antiviral effect of pollen is extremely relevant since when immunologic complications like cytokine storm occur, the antiviral treatment alone is not enough and should be combined with appropriate anti-inflammatory treatment (Biancatelli et al., 2020; Zhai et al., 2020) . Therefore, the bee pollen, which is the bee product with high amounts of quercetin, kaempferol, and its derivates (Rzepecka-Stojko et al., 2015) , can be a promising alternative to fight against COVID-19 (Table 2 ).

Bee venom is produced by female worker bees and is composed of several active components, including enzymes (e.g., phospholipase A2

and hyaluronidase), peptides (e.g., melittin, apamin, mast cell degranulating peptide, and adolapin), amino acids, phospholipids, sugars, biogenic amines, volatile compounds, pheromones, and water (>80%) (Wehbe et al., 2019) . At high concentrations, bee venom can induce pain, inflammation, and allergic reactions in humans. Furthermore, it can cause an excessive stress response of the immune system, which often leads to death. On the other hand, low concentrations (up to 5 μg/mL) of this bee product has shown several pharmacological effects in animal models, such as anti-inflammatory, nociceptive, antimicrobial, and antitumoral effects (Memariani et al., 2019; Perumal Samy, Stiles, Franco, Sethi, & Lim, 2017) . Interestingly, the co-incubation of noncytotoxic concentrations of bee venom or melittin, the main component of bee venom, significantly inhibited the replication of the Influenza A virus (PR8) and the respiratory syncytial virus (RSV) (Uddin et al., 2016) . In addition, bee venom significantly enhanced the differentiation of FOXP3-expressing cells in CD4 T cells and mature CD4 thymocytes. It suggests that bee venom stimulates the differentiation of human regulatory T cells, which plays an important role in the immune response against SARS-CoV infection (Caramalho et al., 2015) .

Thus, future in vitro and in vivo studies may elucidate whether the bee venom and its components can be used as an antiviral agent against SARS-CoV-2 or as an immune system activator against COVID-19 (Table 2 ). In addition, the toxicity of melittin can be reduced by chemical strategies, such as conjugation with polyethylene glycol (PEGylation), truncation, and synthesis of the peptide with dextrogenous (D-)amino acids (Memariani et al., 2019) . These approaches would minimize the toxicity of bee venom and allow the use of higher concentrations of this bee product against viral infections.

Bee products are known for their several medicinal and pharmaceutical properties, which have been explored since the beginning of society. Of these, the antiviral effect and the ability to stimulate the immune system using bee products stand out as potentially promising alternative in the therapy of severe viral respiratory infections, such as COVID-19. Moreover, except for bee venom, apicomplexes are generally well tolerated and readily available, which can contribute to wide access in times of pandemic. The immunomodulatory, antiviral, anti-inflammatory, antioxidant, and pro-resolving effects of different bee products and their chemical components can be useful in prophylaxis, specific treatment, and even symptomatic treatment of COVID-19. However, the number of current evidence is overwhelming, and large randomized and controlled clinical trials should be conducted to assess the real benefit of apitherapy against SARS-CoV-2. In this direction, here, we present the numerous possibilities of apitherapy in combating COVID-19 and highlight the importance of bee products as a promising source of therapeutic and prophylactic strategies against this emergent public health crisis.

William G. Lima is grateful to Coordenação de Aperfeiçoamento de Pessoal do Nível Superior (CAPES) for a PhD fellowship.

Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19)

Composition and functional properties of propolis (bee glue): A review

Effects of propolis, royal jelly, honey and bee pollen on growth performance and immune system of Japanese quails

Antioxidant properties of flavonoids

Quercetin and vitamin C: An experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2

Molecular targets for the rational design of drugs to inhibit SARS coronavirus

A review of selected bee products as potential antibacterial, antifungal, and antiviral agents

Bee venom enhances the differentiation of human regulatory T cells

Polyphenols and palynological origin of bee pollen of Apis mellifera L. from Brazil. Characterization of polyphenols of bee pollen

Human coronavirus types

Binding interaction of quercetin-3-β-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: Structure-activity relationship studies reveal salient pharmacophore features

Quercetin 3-rhamnoside exerts antiinfluenza A virus activity in mice

Phenolic compounds in honey and their associated health benefits: A review

Antiviral effect of methylated flavonol isorhamnetin against influenza

Composición y propiedades de la miel de Apis mellifera: una revisión

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19

Biological and therapeutic properties of bee pollen: A review

Antioxidant and antimicrobial properties of monofloral bee pollen

Inhibitory effect of propolis and royal jelly on some viruses

Clinical value of royal jelly and propolis against viral infections

Jelleines: A family of antimicrobial peptides from the Royal Jelly of honeybees

Royal jelly: An ancient remedy with remarkable antibacterial properties. Microbiological Research

Beeswax: A minireview of its antimicrobial activity and its application in medicine

Quercetin inhibits rhinovirus replication in vitro and in vivo

Silico Approach of Some Selected Honey Constituents as SARS-CoV-2 Main Protease (COVID-19) Inhibitors. ChemRxiv

Antiviral effect of flavonoids on human viruses

Role of dietary antioxidants in human metapneumovirus infection

In vivo activity assessment of a "honey-bee pollen mix" formulation

Antiviral effects and possible mechanisms of action of constituents from Brazilian propolis and related compounds

Co-infections in people with COVID-19: A systematic review and meta-analysis

Identification, genotypic relation, and clinical features of colistin-resistant isolates of acinetobacter genomic species 13BJ/14TU from bloodstreams of patients in a university hospital

Therapeutic drugs targeting 2019-nCoV main protease by high-throughput screening

Human coronaviruses: A review of virus-host interactions

Antimicrobial activity of bee pollen ethanolic and methanolic extracts on Staphylococcus aureus bacterial strain

Melittin: From honeybees to superbugs

Role of honey in modern medicine

Monitoring of the antiviral potential of bee venom and wax extracts against adeno -7 (DNA) and Rift Valley fever virus (RNA) viruses models

Anti-inflammatory activity of natural dietary flavonoids

Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; coronavirus Disease-19)

Animal venoms as antimicrobial agents

Natural compounds as inhibitors of SARS-CoV-2 main protease (3CLpro): A molecular docking and simulation approach to combat COVID-19

Polyphenols from bee pollen: Structure, absorption, metabolism and biological activity

Honey and health: A review of recent clinical research

Antiviral activity and mode of action of propolis extracts and selected compounds

Kaempferol derivatives as antiviral drugs against the 3a channel protein of coronavirus

Anti-influenza virus activity of propolis in vitro and its efficacy against influenza infection in mice

The chemical and biological properties of propolis. Bee Products -Chemical and Biological Properties

Anti-human rhinovirus 2 activity and mode of action of quercetin-7-glucoside from Lagerstroemia speciosa

Standard methods for Apis mellifera beeswax research

A royal jelly as a new potential immunomodulator in rats and mice

Effect of Brazilian propolis on exacerbation of respiratory syncytial virus infection in mice exposed to tetrabromobisphenol A, a brominated flame retardant

Composition and functionality of bee pollen: A review

Inhibitory effects of bee venom and its components against viruses in vitro and in vivo

Anti-influenza viral effects of honey in vitro: Potent high activity of Manuka honey

Bee venom: Overview of main compounds and bioactivities for therapeutic interests

Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells

The epidemiology, diagnosis and treatment of COVID-19

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial

A novel coronavirus from patients with pneumonia in China

Bee products as a source of promising therapeutic and chemoprophylaxis strategies against COVID-19

The authors declare that they have no financial interests or personal relationships that may appear to influence the work reported in this article.

https://orcid.org/0000-0001-8946-9363Júlio C. M. Brito https://orcid.org/0000-0003-2794-5680Waleska S. da Cruz Nizer https://orcid.org/0000-0002-5134-719X